| Name | Title | Contact Details |
|---|
Synonym is accelerating the worlds biological future by developing, financing and building commercial-scale biomanufacturing facilities. We provide synthetic biology (synbio) producers – from startups to the Fortune 500 – with flexible production capacity while giving infrastructure investors access to a new, carbon-negative biomanufacturing asset class that we are calling "fermentation farms".
Precision Machining & World-Wide Distribution Center Paragon is a World Class Global Precision Supplier specializing in the Machining and Assembly of Ferrous / Non Ferrous Components for the Automotive and Non Automotive Industries. Our Customers experience Superior Quality, Competitive Cost, and Attentive Service.
The Odessa Roughnecks is a professional indoor football team based in Odessa, Texas. The teams nickname is a tribute to the oil industry, which has been the source of Odessas wealth over the past century. The team began operations in 2004 as a charter member of the Intense Football League. In 2005, the Intense Football League merged with the National Indoor Football League. For the 2006 season, the Intense Football League was resurrected, and the Odessa Roughnecks returned to their original league. In 2008 the Intense Football League merged again, this time with United Indoor Football to create the Indoor Football League. The team plays its home games at the Ector County Coliseum in Odessa. The teams founder and owner was Tommy Benizio until he resigned to become the IFLs commissioner. In September 2008, the Roughnecks were purchased by the ownership group Allegiance Pro Sports, Inc., led by President & CEO Brandon Smith, a Odessa native, local business owner and 1991 graduate of Odessa High School. The Roughnecks are coached by Chris Williams (former head coach of the Tennessee Valley Vipers of the af2 and was the Roughnecks first head coach). The 2009 season will be Coach Williamss sixth season with the Roughnecks. The Roughnecks won its first championship in 2006 at Intense Bowl 2, beating the Corpus Christi Hammerheads by a score of 97-56, which was an Intense Football League record for most points scored by one team in a game. The team finished with an overall record of 14-2.
Phillip Jeffries Ltd is a family-run company that specializes in the manufacture and importation of high-quality, unique, and textured wallcoverings. Founded in 1976 by Eric Bershad, the company has established itself as a global leader in the industry, offering an extensive range of over 1,000 natural wallcoverings. Their product lineup includes Japanese paper weaves, gold leaf, grasscloth, silks, and unique hand-crafted specialties, all crafted by skilled artisans to ensure exceptional quality and aesthetic appeal. The company is led by Eric Bershads sons, Philip and Jeffrey Bershad, who serve as President and Chief Executive Officer, respectively. This family involvement helps maintain the companys mission and values. Phillip Jeffries is known for its commitment to fast delivery, making it a preferred choice for interior designers, architects, and high-end homeowners seeking distinctive wallcovering solutions.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.